B Lymphoblastic Leukemia/Lymphoma — Trials

B Lymphoblastic Leukemia/Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 163
Recruiting: 102
Ph III recruiting: 11
Growth YoY: +17.2%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 43.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (49)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03677596	A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients	completed	Phase 4	102	PfizerINDUSTRY	8	Nov 22, 2023	clinicaltrials
NCT02618109	Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia(LABMI)	terminated	Phase 4	119	University Hospital, AngersOTHER_GOV	1	Oct 3, 2022